Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Evaluate the Efficacy and Safety of Topical BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers

NCT06383013 is registered in ClinicalTrials.gov with Blue Blood Biotech Corp. as lead sponsor.

NCT NCT06383013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06383013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Evaluate the Efficacy and Safety of Topical BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers
Lead sponsor
Blue Blood Biotech Corp.
Phase
Phase 2
Overall status
Recruiting
Start date
May 1, 2024
Completion date
December 31, 2028
Enrollment
96 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic foot ulcer